SGEN stock: buy or sell?
August 22nd, 2019
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide.
Should I buy SGEN stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. That's why is so important to define your own trading strategy that fits your character as inversor. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Seattle Genetics stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Seattle Genetics stock a buy?
Banks and financial institutions publish stock ratings everyday.At Stocks2.com, we detected 8 ratings published for SGEN stock in the last 30 days. The general sentiment of these ratings is bullish for SGEN stock, with 7 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-7-17||Piper Jaffray Companies||Neutral||Overweight|
|2019-4-5||Royal Bank of Canada||Outperform||Outperform|
|2019-1-10||JPMorgan Chase & Co.||n/a||Buy|
SGEN stock analysis
Seattle Genetics shares eased -2.01% to $78.36 today.
Seattle Genetics shares eased -2.01% to $78.36 today. In the last 36 days when SGEN stock price broke up the SMA200d line, it gained $15.18 (24.03%). On May, SMA100d and SMA200d crossed up triggering a rise of 14.49%. From a daily perspective, SGEN is in a short term uptrend after plotting its last bottom ($72.51, on August/5) higher than the previous bottom, and its last top ($80.29, yesterday) also over the previous top. Now trading in between its last bottom and last top SGEN might consolidate in a plain range, waiting to break out over $80.29 or down under $72.51.
Seattle Genetics shares depreciated -1.06% this week, ending at $78.36. By mid July SGEN rocketed an astounding 15.04% in just one week. Early July SGEN plunged a frightening -8.26% in just one week.
By mid July SGEN price bounced up over the SMA of 40 weeks that acted as support stopping new slides. Late April, SMA20w and SMA40w crossed up triggering a rise of 13.27%. Far behind is the all-time high Seattle Genetics marked early October but price is just -7.12% below that top.
SGEN stock price history
SGEN IPO was on March 9th, 2001 at $8.88 per share1. Since then, SGEN stock grew a 782.40%, with an average of 43.50% per year. If you had invested $1,000 in SGEN stock in 2001, it would worth $7,824.00 today.
1: Adjusted price after possible price splits or reverse-splits.
SGEN stock historical price chart
SGEN stock reached all-time highs on October with a price of $84.37.
SGEN stock price target is $85.50Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' SGEN stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we found 4 price forecasts for Seattle Genetics stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-7-17||Piper Jaffray Companies||Upgrades||$64.00||$75.00||17.2%|
|2019-4-5||Royal Bank of Canada||Raises Target||$89.00||$90.00||1.1%|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, Seattle Genetics presented its financial report, posting an outstanding climb for the Earnings per Share (EPS) ratio. Experts expected $-0.39 per share, but Seattle Genetics posted $-0.57.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual sales report draw an exceptional growth of 35.76% to $654.70 M dollars. When comparing 2018 vs 2017, nevertheless, profit margin (that is, the net income divided by revenues) dropped a -7.98% to -34.01%.
|2013||$269 M||-||$-62.52 M-23.2%||-|
|2014||$287 M||6.50%||$-76.14 M-26.6%||21.79%|
|2015||$337 M||17.45%||$-120.49 M-35.8%||58.24%|
|2016||$418 M||24.15%||$-140.11 M-33.5%||16.29%|
|2017||$482 M||15.33%||$-125.53 M-26.0%||-10.41%|
|2018||$655 M||35.76%||$-222.69 M-34.0%||77.40%|
Quarterly financial resultsSeattle Genetics reported $174.51 M in revenues for 2018-Q4, a 3.00% improvement compared to previous quarter. Reported quarter income marked $-119.81 M with a profit margin of -68.65%. Profit margin collapsed a -28.84% compared to previous quarter when profit margin was -39.81%. When comparing revenues to same quarter last year, Seattle Genetics sales marked an amazing increase and skyrocketed a 34.65%.
|2017-Q2||$108 M||-||$-56.36 M-52.1%||-|
|2017-Q3||$135 M||25.01%||$50.02 M37.0%||-188.75%|
|2017-Q4||$130 M||-4.20%||$-59.20 M-45.7%||-218.35%|
|2018-Q1||$141 M||8.48%||$-111.72 M-79.5%||88.70%|
|2018-Q2||$170 M||21.04%||$76.27 M44.8%||-168.27%|
|2018-Q3||$169 M||-0.44%||$-67.45 M-39.8%||-188.43%|
|2018-Q4||$175 M||3.00%||$-119.81 M-68.7%||77.63%|
|2019-Q1||$195 M||11.85%||$-13.33 M-6.8%||-88.87%|
Seattle Genetics ownershipWhen you are planning to buy shares of a company, it's always worth to overview its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Seattle Genetics, 1.16% of all outstanding shares are owned by its staff.
Bearish positions for SGEN stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related stocks:
|Market cap||$12.6 B||$100.0 B||$45.2 B||$77.9 B||$67.1 B|
|Total shares||161.0 M||1,480.0 M||193.9 M||1,630.0 M||701.0 M|
|Float shares||112.1 M||1,480.0 M||184.0 M||1,630.0 M||706.3 M|
|- Institutional holdings (%)||106.9%||71.9%||93.4%||75.0%||77.6%|
|- Insider holdings (%)||1.2%||0.1%||0.5%||0.1%||0.2%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Thursday, August 22nd, 2019|
|Day range||$77.06 - $80.06|
|Average true range||$2.47|
|50d mov avg||$72.75|
|100d mov avg||$71.33|
|200d mov avg||$68.78|
Seattle Genetics performanceTo measure stock performance is always good to benchmark with competitors or related stocks. In the following table, we compare Seattle Genetics to AbbVie, Biogen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, ImmunoGen, Pfizer, Progenics Pharmaceuticals and Spectrum Pharmaceuticals:
Seattle Genetics competitorsOne check before trading any stock is to have a look a list of its competitors, in this case for Seattle Genetics. We picked 9 companies as Seattle Genetics competitors as they are in the same industry or have similar market objectives.
- AbbVie (ABBV)
- Biogen (BIIB)
- Bristol-Myers Squibb (BMY)
- Celgene (CELG)
- GlaxoSmithKline (GSK)
- ImmunoGen (IMGN)
- Pfizer (PFE)
- Progenics Pharmaceuticals (PGNX)
- Spectrum Pharmaceuticals (SPPI)
Latest SGEN stock news
- Seeking AlphaSeattle Genetics: Commercial Portfolio Expanding, Tucatinib Data In SightJuly 4, 2019
- Seeking AlphaCancer Research Highlight: Bristol-Myers And Seattle Genetics Put The Full Court Press On Aggressive LymphomaDecember 6, 2018
- Seeking AlphaCancer Research Highlight: Seattle Genetics Moves The Chains In T-Cell LymphomaOctober 4, 2018
- Seeking AlphaSeattle Genetics Is A Solid Buy In 2018August 27, 2018